Company Performance - Waters reported quarterly earnings of $2.95 per share, exceeding the Zacks Consensus Estimate of $2.93 per share, and up from $2.63 per share a year ago, representing an earnings surprise of +0.68% [1] - The company posted revenues of $771.33 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.63%, compared to $708.53 million in the same quarter last year [2] - Over the last four quarters, Waters has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Waters shares have declined approximately 21.8% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The consensus EPS estimate for the upcoming quarter is $3.24 on revenues of $777.06 million, and for the current fiscal year, it is $12.91 on revenues of $3.11 billion [7] Industry Context - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Core Viewpoint - iRadimed (IRMD) reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.42 per share a year ago, indicating a positive earnings surprise of +8.89% [1] Group 1: Earnings Performance - The company achieved revenues of $20.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.49% and up from $17.93 million year-over-year [2] - Over the last four quarters, iRadimed has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - iRadimed shares have increased approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.8% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.44 for the upcoming quarter and $1.76 for the current fiscal year [7] Group 3: Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Core Insights - Waters (WAT) reported quarterly earnings of $2.25 per share, exceeding the Zacks Consensus Estimate of $2.22 per share, and showing a slight increase from $2.21 per share a year ago, resulting in an earnings surprise of 1.35% [1] - The company achieved revenues of $661.71 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.08% and reflecting a year-over-year increase from $636.84 million [2] - Waters has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Waters' stock will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.93, with projected revenues of $737.31 million, and for the current fiscal year, the consensus EPS is $12.84 on revenues of $3.08 billion [7] Industry Context - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Group 1 - Idexx Laboratories reported quarterly earnings of $2.96 per share, exceeding the Zacks Consensus Estimate of $2.92 per share, and showing an increase from $2.81 per share a year ago, representing an earnings surprise of 1.37% [1] - The company posted revenues of $998.43 million for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 1.77%, but an increase from $964.1 million year-over-year [2] - Idexx has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times during the same period [2] Group 2 - The stock has gained approximately 4.7% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current consensus EPS estimate for the upcoming quarter is $3.26 on revenues of $1.06 billion, and for the current fiscal year, it is $11.96 on revenues of $4.09 billion [7] - The Medical - Instruments industry, to which Idexx belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]